
    
      This study is Multi-center, Open-label, Randomized Controlled Phase 4 Study to Evaluate the
      Efficacy and Safety of RaparoBellÂ® Tablet Plus Calcineurin Inhibitors Compared with
      Mycophenolate Mofetil Plus Calcineurin Inhibitors in ABO incompatible De Novo Living Kidney
      Transplant Recipients.
    
  